Canadian Recommendations for Biomarker Testing in Gastric Cancer
Author Information
Author(s): Brezden-Masley Christine, Fiset Pierre O., Cheung Carol C., Arnason Thomas, Bateman Justin, Borduas Martin, Evaristo Gertruda, Ionescu Diana N., Lim Howard J., Sheffield Brandon S., Soldera Sara V., Streutker Catherine J.
Primary Institution: University of Toronto
Hypothesis
The study aims to provide guidance on predictive biomarker testing for gastric and gastroesophageal junction adenocarcinoma in Canada.
Conclusion
The expert working group recommends reflex testing for several biomarkers at the time of diagnosis to improve treatment decision-making for patients with gastric and gastroesophageal junction adenocarcinoma.
Supporting Evidence
- Biomarker testing is essential for selecting appropriate therapies for gastric cancer.
- Reflex testing improves the rate and speed of biomarker testing.
- Current guidelines recommend testing for HER2, MMR, MSI, PD-L1, and CLDN18.
Takeaway
Doctors should test for specific markers in stomach cancer patients right away to help choose the best treatment.
Methodology
A multidisciplinary expert working group developed consensus recommendations based on literature review and expert opinion.
Potential Biases
The working group was funded by Astellas Canada, but members were selected independently.
Limitations
The recommendations may not cover all potential biomarkers as new therapies emerge.
Participant Demographics
The working group included pathologists and oncologists from major Canadian provinces.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website